Renin-angiotensin system (ACEIs and/or ARBs) (versus unexposed) updated on 03-11-2025

Early intrauterine deaths (< 22 weeks) / Spontaneous abortions

R analysis
id Study   Lib. in paper Exposition period    Study type  Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S17123
R71686
Van der Zande - ACE-Is and/or ARBs, 2024 Reported miscarriage (NOS) 1st trimester prospective cohort unexposed, sick Adjustment: No Indications Antihypertensive: Only cardiac indications other than hypertension (long QT syndrome, structural heart disease, ...) Renin angiotensin: ARBs and/or ACEIs (Angiotensin II receptor blockers and/or Angiotensin-converting enzyme inhibitors) 2.52 [0.76;8.30] C 3/34   211/5,697 214 34
ref
S14147
R55481
Hoeltzenbein a - ARBs, 2018 Spontaneous abortion early pregnancy prospective cohort unexposed, disease free Adjustment: Yes Indications Antihypertensive: Only chronic hypertension indication Matched Renin angiotensin: ARBs (Angiotensin II receptor blockers) 0.90 [0.50;1.60] 26/215   57/642 83 215
ref
S14149
R55510
Hoeltzenbein b - ACEi, 2018 Spontaneous abortions early pregnancy prospective cohort unexposed, disease free Adjustment: Yes Indications Antihypertensive: Only chronic hypertension indication Matched Renin angiotensin: ACEIs (Angiotensin-converting enzyme inhibitors) 1.20 [0.74;1.92] 47/329   54/654 101 329
ref
S14158
R55559
Moretti - ACEi/ARBs, 2012 Spontaneous abortion 1st trimester prospective cohort unexposed, disease free Adjustment: No Indications Antihypertensive: All hypertensions, any indications or not specified Matched Renin angiotensin: ARBs and/or ACEIs (Angiotensin II receptor blockers and/or Angiotensin-converting enzyme inhibitors) 1.67 [0.85;3.29] C 25/139   16/138 41 139
ref
S14145
R55543
Diav-Citrin - ACEi/ARB, 2011 Miscarriage early pregnancy prospective cohort unexposed (general population or NOS) Adjustment: No Indications Antihypertensive: All hypertensions, any indications or not specified Renin angiotensin: ARBs and/or ACEIs (Angiotensin II receptor blockers and/or Angiotensin-converting enzyme inhibitors) 1.95 [1.14;3.31] C 29/252   31/495 60 252
ref
S14146
R55476
Cournot - ACEi, 2006 Spontaneous abortions 1st trimester prospective cohort unexposed (general population or NOS) Adjustment: No Indications Antihypertensive: All hypertensions, any indications or not specified Matched Renin angiotensin: ACEIs (Angiotensin-converting enzyme inhibitors) 1.46 [0.54;3.93] C 10/159   7/159 17 159
ref
Total 6 studies 1.41 [1.07;1.84] 516 1,128
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Van der Zande - ACE-Is and/or ARBs, 2024Van der Zande - ACE-Is and/or ARBs, 2024 2.52[0.76; 8.30]214345%ROB confusion: criticalROB selection: lowROB classification: criticalROB missing: unclearROB mesure: moderateROB reporting: moderate Hoeltzenbein a - ARBs, 2018Hoeltzenbein a - ARBs, 2018 0.90[0.50; 1.60]8321520%ROB confusion: seriousROB selection: moderateROB classification: moderateROB missing: lowROB mesure: unclearROB reporting: moderate Hoeltzenbein b - ACEi, 2018Hoeltzenbein b - ACEi, 2018 1.20[0.74; 1.92]10132929%ROB confusion: seriousROB selection: moderateROB classification: moderateROB missing: lowROB mesure: criticalROB reporting: moderate Moretti - ACEi/ARBs, 2012Moretti - ACEi/ARBs, 2012 1.67[0.85; 3.29]4113915%ROB confusion: criticalROB selection: moderateROB classification: moderateROB missing: lowROB mesure: criticalROB reporting: moderate Diav-Citrin - ACEi/ARB, 2011Diav-Citrin - ACEi/ARB, 2011 1.95[1.14; 3.31]6025224%ROB confusion: criticalROB selection: moderateROB classification: moderateROB missing: lowROB mesure: unclearROB reporting: moderate Cournot - ACEi, 2006Cournot - ACEi, 2006 1.46[0.54; 3.93]171597%ROB confusion: criticalROB selection: moderateROB classification: moderateROB missing: unclearROB mesure: unclearROB reporting: moderate Total (6 studies) I2 = 6% 1.41[1.07; 1.84]5161,1280.210.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 1.41[1.07; 1.84]5161,1286%NAVan der Zande - ACE-Is and/or ARBs, 2024 Hoeltzenbein a - ARBs, 2018 Hoeltzenbein b - ACEi, 2018 Moretti - ACEi/ARBs, 2012 Diav-Citrin - ACEi/ARB, 2011 Cournot - ACEi, 2006 6 case control studiescase control studies 0 Type of controls unexposed (disease free or unspecified)unexposed (disease free or unspecified) 1.36[1.03; 1.80]3021,0948%NAHoeltzenbein a - ARBs, 2018 Hoeltzenbein b - ACEi, 2018 Moretti - ACEi/ARBs, 2012 Diav-Citrin - ACEi/ARB, 2011 Cournot - ACEi, 2006 5 unexposed, sickunexposed, sick 2.52[0.76; 8.30]21434 -NAVan der Zande - ACE-Is and/or ARBs, 2024 1 Tags Adjustment   - No  - No 1.83[1.27; 2.65]3325840%NAVan der Zande - ACE-Is and/or ARBs, 2024 Moretti - ACEi/ARBs, 2012 Diav-Citrin - ACEi/ARB, 2011 Cournot - ACEi, 2006 4   - Yes  - Yes 1.07[0.74; 1.55]1845440%NAHoeltzenbein a - ARBs, 2018 Hoeltzenbein b - ACEi, 2018 2 Indications Antihypertensive   - All hypertensions, any indications ...  - All hypertensions, any indications or not specified 1.77[1.21; 2.61]1185500%NAMoretti - ACEi/ARBs, 2012 Diav-Citrin - ACEi/ARB, 2011 Cournot - ACEi, 2006 3   - Only cardiac indications other than ...  - Only cardiac indications other than hypertension (long QT syndrome, structural heart disease, ...) 2.52[0.76; 8.30]21434 -NAVan der Zande - ACE-Is and/or ARBs, 2024 1   - Only chronic hypertension indication  - Only chronic hypertension indication 1.07[0.74; 1.55]1845440%NAHoeltzenbein a - ARBs, 2018 Hoeltzenbein b - ACEi, 2018 2 MatchedMatched 1.21[0.89; 1.64]2428420%NAHoeltzenbein a - ARBs, 2018 Hoeltzenbein b - ACEi, 2018 Moretti - ACEi/ARBs, 2012 Cournot - ACEi, 2006 4 Renin angiotensin   - ACEIs (Angiotensin-converting enzym ...  - ACEIs (Angiotensin-converting enzyme inhibitors) 1.24[0.81; 1.91]1184880%NAHoeltzenbein b - ACEi, 2018 Cournot - ACEi, 2006 2   - ARBs (Angiotensin II receptor blockers)  - ARBs (Angiotensin II receptor blockers) 0.90[0.50; 1.61]83215 -NAHoeltzenbein a - ARBs, 2018 1   - ARBs and/or ACEIs (Angiotensin II r ...  - ARBs and/or ACEIs (Angiotensin II receptor blockers and/or Angiotensin-converting enzyme inhibitors) 1.90[1.28; 2.82]3154250%NAVan der Zande - ACE-Is and/or ARBs, 2024 Moretti - ACEi/ARBs, 2012 Diav-Citrin - ACEi/ARB, 2011 3 All studiesAll studies 1.41[1.07; 1.84]5161,1286%NAVan der Zande - ACE-Is and/or ARBs, 2024 Hoeltzenbein a - ARBs, 2018 Hoeltzenbein b - ACEi, 2018 Moretti - ACEi/ARBs, 2012 Diav-Citrin - ACEi/ARB, 2011 Cournot - ACEi, 2006 60.210.01.0

Publication bias and p-hacking diagnosis

funnel plot
0.0-1.41.80.7300.000Van der Zande - ACE-Is and/or ARBs, 2024Hoeltzenbein a - ARBs, 2018Hoeltzenbein b - ACEi, 2018Moretti - ACEi/ARBs, 2012Diav-Citrin - ACEi/ARB, 2011Cournot - ACEi, 2006

Asymetry test p-value = 0.4551 (by Egger's regression)

slope=-0.0485 (0.4887); intercept=1.2431 (1.5045); t=0.8263; p=0.4551

p values plot
0.01.00.01.0

Sub-groups analysis using all included studies

excluded

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) 1.36[1.03; 1.80]3021,0948%NAHoeltzenbein a - ARBs, 2018 Hoeltzenbein b - ACEi, 2018 Moretti - ACEi/ARBs, 2012 Diav-Citrin - ACEi/ARB, 2011 Cournot - ACEi, 2006 5 unexposed, sick controlsunexposed, sick controls 2.52[0.76; 8.30]21434 -NAVan der Zande - ACE-Is and/or ARBs, 2024 10.510.01.0

Umbrella review (other published meta-analyses)

Published MAControlPeriodTE95% CIn exposedkI2 Buawangpong (ACEi/ARBs) (Miscarriage)Buawangpong (ACEi/ARBs) (Miscarriage) 1.63[1.30; 2.05]4%-Wwhatever (meta-analysis)T11st trimesterstudies TTT6 Buawangpong (ACEi/ARBs) (Miscarriage)Buawangpong (ACEi/ARBs) (Miscarriage) 1.63[1.30; 2.05]4%-Wwhatever (meta-analysis)Anyduring pregnancy (anytime or not specified)studies TTT6 Fu (ACEi/ARBs) (Spontaneous miscarriage (vers ...Fu (ACEi/ARBs) (Spontaneous miscarriage (versus exposed to other oral antihypertensives)) 2.03[0.25; 16.18]75%-Eexposed to other treatment, sickT1+at least 1st trimesterstudies TTT3 Fu (ACEi/ARBs) (Spontaneous miscarriage (vers ...Fu (ACEi/ARBs) (Spontaneous miscarriage (versus non‐exposed controls)) 1.56[0.96; 2.52]0%-Wwhatever (meta-analysis)T1+at least 1st trimesterstudies TTT4 metaPregmetaPreg 1.41[1.07; 1.84]6%1,128----Van der Zande - ACE-Is and/or ARBs, 2024 Hoeltzenbein a - ARBs, 2018 Hoeltzenbein b - ACEi, 2018 Moretti - ACEi/ARBs, 2012 Diav-Citrin - ACEi/ARB, 2011 Cournot - ACEi, 2006 60.510.01.0